DEBIOPHARM EXTENDS THEIR DNA DAMAGE REPAIR FOOTPRINT WITH NEW ONCOLOGY PIPELINE ENTRY
(Adnkronos) – Debiopharm obtains global rights from Novo Nordisk for the development of their ubiquitin-specific protease 1 (USP1) inhibitor LAUSANNE, Switzerland, March 2, 2023 /PRNewswire/ — Debiopharm (www.debiopharm.com), an independent Swiss-based, biopharmaceutical
